Back to Journals » International Journal of Nanomedicine » Volume 10 » Issue 1

Review on lipegfilgrastim

Authors Gasparic M, Leyman S

Received 15 September 2015

Accepted for publication 17 September 2015

Published 3 November 2015 Volume 2015:10(1) Pages 6863—6864

DOI https://doi.org/10.2147/IJN.S96413

Editor who approved publication: Dr Thomas J Webster

Maja Gasparic, Sophie Leyman

Teva Pharmaceuticals Europe BV, European Headquarters, Amsterdam, the Netherlands

Having read the original Hoggatt et al article1 and the corrigendum published online on August 27, 2015,2 we do not consider the description of lipegfilgrastim to be entirely accurate, and we would therefore like to clarify what lipegfilgrastim actually is.
The description of lipegfilgrastim used in the original article was a “long-acting biosimilar filgrastim”.1 This description was subsequently amended in the corrigendum to “lipegfilgrastim has an active substance that is similar to filgrastim, with similar pharmacokinetics, receptor binding affinity, safety and efficacy as pegfilgrastim”.2
 
 
Read the Corrigendum


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Enhanced bioavailability of nerve growth factor with phytantriol lipid-based crystalline nanoparticles in cochlea

Bu M, Tang J, Wei Y, Sun Y, Wang X, Wu L, Liu H

International Journal of Nanomedicine 2015, 10:6879-6889

Published Date: 3 November 2015

Photosensitizer and peptide-conjugated PAMAM dendrimer for targeted in vivo photodynamic therapy

Narsireddy A, Vijayashree K, Adimoolam MG, Manorama SV, Rao NM

International Journal of Nanomedicine 2015, 10:6865-6878

Published Date: 3 November 2015

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Acquired hemophilia A: emerging treatment options

Janbain M, Leissinger CA, Kruse-Jarres R

Journal of Blood Medicine 2015, 6:143-150

Published Date: 8 May 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A

Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S

Neuropsychiatric Disease and Treatment 2014, 10:865-867

Published Date: 16 May 2014

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010